LIPOXEN TECHNOLOGIES LIMITED

Active London

Research and experimental development on biotechnology

1 employees website.com
Research and experimental development on biotechnology
L

LIPOXEN TECHNOLOGIES LIMITED

Research and experimental development on biotechnology

Founded 10 Jul 1997 Active London, United Kingdom 1 employees website.com
Research and experimental development on biotechnology

Previous Company Names

LIPOXEN LIMITED 10 Jul 1997 — 15 Jun 2000
Accounts Submitted 1 Oct 2025 Next due 30 Sept 2026 4 months remaining
Confirmation Submitted 22 Aug 2025 Next due 24 Jul 2026 2 months remaining
Net assets £-23M £1M 2024 year on year
Total assets £54K £49K 2024 year on year
Total Liabilities £23M £1M 2024 year on year
Charges 1
1 satisfied

Contact & Details

Contact

Registered Address

5th Floor 15 Whitehall London SW1A 2DD

Full company profile for LIPOXEN TECHNOLOGIES LIMITED (03401495), an active company based in London, United Kingdom. Incorporated 10 Jul 1997. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Balance Sheet & P&L (2014–2024)

Cash in Bank

£47.57k

Increased by £45.00k (+1750%)

Net Assets

-£23.11M

Increased by £1.44M (+6%)

Total Liabilities

£23.16M

Decreased by £1.39M (-6%)

Turnover

£2.00M

Increased by £3.17k (+0%)

Employees

1

Debt Ratio

42542%

Decreased by 447375 (-91%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Xenetic Biosciences (uk) Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent

Group Structure

Group Structure

LIPOXEN TECHNOLOGIES LIMITED Current Company

Charges

Charges

1 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
1 Oct 2025AccountsAnnual accounts made up to 31 Dec 2024
22 Aug 2025Confirmation StatementConfirmation statement made on 10 Jul 2025 with no updates
20 Jun 2025OfficersChange to director Mr Colin William Hill on 11 Jun 2025
27 Sept 2024AccountsAnnual accounts made up to 31 Dec 2023
19 Jul 2024Confirmation StatementConfirmation statement made on 10 Jul 2024 with no updates
1 Oct 2025 Accounts

Annual accounts made up to 31 Dec 2024

22 Aug 2025 Confirmation Statement

Confirmation statement made on 10 Jul 2025 with no updates

20 Jun 2025 Officers

Change to director Mr Colin William Hill on 11 Jun 2025

27 Sept 2024 Accounts

Annual accounts made up to 31 Dec 2023

19 Jul 2024 Confirmation Statement

Confirmation statement made on 10 Jul 2024 with no updates

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2024

7 months ago on 1 Oct 2025

Confirmation statement made on 10 Jul 2025 with no updates

8 months ago on 22 Aug 2025

Change to director Mr Colin William Hill on 11 Jun 2025

10 months ago on 20 Jun 2025

Annual accounts made up to 31 Dec 2023

1 years ago on 27 Sept 2024

Confirmation statement made on 10 Jul 2024 with no updates

1 years ago on 19 Jul 2024